Breaking News Instant updates and real-time market news.

MDT

Medtronic

$97.85

0.38 (0.39%)

12:26
09/23/18
09/23
12:26
09/23/18
12:26

Clinical study shows safety, efficacy outcomes for Medtronic Resolute Onyx DES

Investigators unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of the durable polymer Resolute Onyx drug-eluting stent from Medtronic to the Orsiro biodegradable polymer stent. At one year, the study showed patients with coronary artery disease who were treated with Orsiro BP-DES received no clinical advantage compared to patients treated with the Resolute Onyx DP-DES, and Orsiro BP-DES demonstrated a higher rate of stent thrombosis. Enrolling approximately 2,500 real-world patients, the BIONYX study had a primary composite endpoint of target vessel failure at one-year and showed no statistically significant difference in outcomes for the Resolute Onyx DP-DES treated group at 4.5% compared to 4.7% with the Orsiro BP-DES. However, notable differences were observed in significantly lower rates of definite or probable stent thrombosis at one year. The Resolute Onyx DES is coated with the proprietary BioLinx polymer, a bio-compatible and non-thrombogenic coating specifically designed for use on DES. Low rates of stent thrombosis have been observed in more than 70,000 real-world clinical study patients, with additional studies underway, including the global Medtronic Onyx ONE Month DAPT Program comprised of two studies designed to investigate safety following one-month of dual anti-platelet therapy discontinuation post-PCI. The Resolute Onyx DES offers the broadest size matrix available and is the first-and-only DES to feature Core Wire Technology which enables thinner struts and greater deliverability while maintaining structural strength and enhanced visibility.

  • 09

    Oct

MDT Medtronic
$97.85

0.38 (0.39%)

09/13/18
PIPR
09/13/18
NO CHANGE
Target $58
PIPR
Overweight
Globus Medical Nemaris acquisition to be modest contributor, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $58 price target on Globus Medical (GMED), saying the company's acquisition of Nemaris announced earlier today should be a "modest revenue contributor". The analyst estimates the price tag around $20M. Longer term, the analyst expects Nemaris' marketed Surgimap to bring help to the company in terms of staying ahead of Medtronic (MDT) in the surgical planning category.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $105
PIPR
Overweight
Medtronic acquisition of Mazor not a surprise, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Medtronic's (MDT) $1.64B acquisition of Mazor Robotics (MZOR) is not much of a surprise given the companies' exclusive distribution arrangement and Medtronic's existing minority stake. The deal will help Medtronic's spine franchise business stay on the road to recovery, O'Brien tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target. Further, the analyst believes robot placements are "still in the early days" and that the acquisition will not "overly hurt" Globus Medical's (GMED) ability to sell systems in coming quarters. As such, O'Brien thinks the Mazor Robotics takeover will unlikely have an impact on Globus's Excelsius robot.
09/21/18
NEED
09/21/18
UPGRADE
NEED
Hold
Mazor Robotics upgraded to Hold from Underperform at Needham
Needham analyst Mike Matson upgraded Mazor Robotics (MZOR) to Hold from Underperform after its announced acquisition by Medtronic (MDT). The analyst notes that other bidders are unlikely to emerge given that Medtronic is "currently the exclusive global distributor of the Mazor X spinal robotics system" and already owns a significant part of the company. Matson adds that since the two companies do not compete in the same segment of the spine market, any anti-trust issues are unlikely to emerge in the regulatory review.
09/21/18
STFL
09/21/18
NO CHANGE
Target $70
STFL
Buy
IntriCon price target raised to $70 from $65 at Stifel
Stifel analyst Jonathan Block raised his price target on IntriCon (IIN) to $70 from $65 by assigning what he called "relatively conservative sales multiples" to his forecasts for the company's Medical and Hearing businesses, but he also contends that margin expansion will play an important part to IntriCon's story in the coming years, giving the stock a path toward $100 per share. Block, who believes IntriCon's traction with Medtronic (MDT) gives it a long runway for growth, keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

02:55
02/20/19
02/20
02:55
02/20/19
02:55
General news
FX Update: The Dollar has traded mostly firmer »

FX Update: The Dollar…

01:55
02/20/19
02/20
01:55
02/20/19
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

LUV

Southwest

$57.66

0.02 (0.03%)

21:49
02/19/19
02/19
21:49
02/19/19
21:49
Downgrade
Southwest rating change at Goldman Sachs »

Southwest downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

RARE

Ultragenyx

$56.80

0.14 (0.25%)

21:17
02/19/19
02/19
21:17
02/19/19
21:17
Recommendations
Ultragenyx analyst commentary at Piper Jaffray »

Piper Jaffray positive on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

21:05
02/19/19
02/19
21:05
02/19/19
21:05
General news
Japan's exports fell 8.4% in January »

Japan's exports fell…

PANW

Palo Alto Networks

$230.19

3.46 (1.53%)

20:49
02/19/19
02/19
20:49
02/19/19
20:49
Downgrade
Palo Alto Networks rating change at Gabelli »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 25

    Feb

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

AROC

Archrock

$10.06

0.365 (3.76%)

20:33
02/19/19
02/19
20:33
02/19/19
20:33
Earnings
Archrock sees FY19 net income $73M-$103M vs. $29.2M in FY18 »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CTL

CenturyLink

$14.10

0.37 (2.69%)

20:32
02/19/19
02/19
20:32
02/19/19
20:32
Downgrade
CenturyLink rating change at RBC Capital »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

TTD

Trade Desk

$161.76

3.69 (2.33%)

20:31
02/19/19
02/19
20:31
02/19/19
20:31
Downgrade
Trade Desk rating change at Stifel »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

CVS

CVS Health

$69.92

0.39 (0.56%)

, SO

Southern Company

$48.91

0.35 (0.72%)

20:25
02/19/19
02/19
20:25
02/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CVS

CVS Health

$69.92

0.39 (0.56%)

SO

Southern Company

$48.91

0.35 (0.72%)

ADI

Analog Devices

$104.21

-1.49 (-1.41%)

HSIC

Henry Schein

$63.11

0.73 (1.17%)

OC

Owens Corning

$55.38

0.73 (1.34%)

WIX

Wix.com

$125.70

4.31 (3.55%)

WWW

Wolverine World Wide

$39.50

-0.04 (-0.10%)

CNDT

Conduent

$14.52

0.93 (6.84%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 09

    Apr

  • 28

    May

AROC

Archrock

$10.06

0.365 (3.76%)

20:21
02/19/19
02/19
20:21
02/19/19
20:21
Earnings
Archrock reports Q4 EPS 10c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AI

Arlington Asset Investment

$8.70

-0.14 (-1.58%)

20:09
02/19/19
02/19
20:09
02/19/19
20:09
Syndicate
Arlington Asset Investment 6M share Spot Secondary priced at $8.33 »

Arlington Asset announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GLD

SPDR Gold Shares

$126.70

1.89 (1.51%)

19:46
02/19/19
02/19
19:46
02/19/19
19:46
Hot Stocks
SPDR Gold Shares holdings fall to 792.45MT from 793.03MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.